CY1111378T1 - Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna - Google Patents

Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna

Info

Publication number
CY1111378T1
CY1111378T1 CY20111100356T CY111100356T CY1111378T1 CY 1111378 T1 CY1111378 T1 CY 1111378T1 CY 20111100356 T CY20111100356 T CY 20111100356T CY 111100356 T CY111100356 T CY 111100356T CY 1111378 T1 CY1111378 T1 CY 1111378T1
Authority
CY
Cyprus
Prior art keywords
cell
cellular dna
low levels
cell culture
viral vaccines
Prior art date
Application number
CY20111100356T
Other languages
English (en)
Inventor
Jens-Peter Gregersen
Holger Kost
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of CY1111378T1 publication Critical patent/CY1111378T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Η παρούσα εφεύρεση σχετίζεται με προϊόντα εμβολίων για την αντιμετώπιση ή πρόληψη ιϊκών μολύνσεων. Περαιτέρω παρέχονται μέθοδοι μείωσης μολυντών που συνδέονται με την παρασκευή εμβολίων κυτταρικής καλλιέργειας. Υπολειμματικό λειτουργικό DNA κυτταρικής καλλιέργειας αποικοδομείται με κατεργασία με έναν DNA αλκυλιωτικό παράγοντα, όπως β-προπιολακτόνη (BPL), παρέχοντας έτσι ένα εμβόλιο το οποίο περιλαμβάνει ανοσογόνες πρωτεΐνες προερχόμενες από έναν ιό πολλαπλασιασμένο σε κυτταρική καλλιέργεια, ουσιαστικά απαλλαγμένο από υπολειμματικό λειτουργικό DNA κυτταρικής καλλιέργεια.
CY20111100356T 2005-11-01 2011-04-05 Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna CY1111378T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
EP06831855.9A EP1951296B2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (1)

Publication Number Publication Date
CY1111378T1 true CY1111378T1 (el) 2015-08-05

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100356T CY1111378T1 (el) 2005-11-01 2011-04-05 Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna

Country Status (19)

Country Link
US (2) US10655108B2 (el)
EP (3) EP2301572B1 (el)
JP (5) JP5602366B2 (el)
KR (1) KR20080081254A (el)
CN (2) CN104474543A (el)
AT (1) ATE494906T1 (el)
AU (2) AU2006310171B2 (el)
CA (1) CA2627971A1 (el)
CY (1) CY1111378T1 (el)
DE (1) DE602006019629D1 (el)
DK (1) DK1951296T4 (el)
EA (1) EA014062B1 (el)
ES (2) ES2525518T3 (el)
HK (2) HK1129837A1 (el)
NZ (1) NZ567817A (el)
PL (2) PL2301572T3 (el)
PT (1) PT2301572E (el)
SI (1) SI1951296T2 (el)
WO (1) WO2007052163A2 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525518T3 (es) * 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
PL2185191T3 (pl) * 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
JP2012507272A (ja) * 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 ｐｏｌ ｉ 프로모터를 사용하는 역 유전학
US9821052B2 (en) 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems
IN2012DN03418A (el) 2009-10-09 2015-10-23 Childrens Medical Center
EP2491117B2 (en) 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
JP6200805B2 (ja) 2010-05-03 2017-09-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
KR20130079398A (ko) * 2010-05-06 2013-07-10 노파르티스 아게 미생물 불활성화를 위한 유기 과산화 화합물
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
BR112012030619A2 (pt) 2010-06-01 2019-09-24 Novartis Ag concentração de antígenos de vacina influenza sem liofilização.
CN103052399B (zh) 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
JP5999817B2 (ja) * 2011-02-25 2016-10-05 ノバルティス アーゲー 外因性の内部陽性対照
MY172501A (en) 2011-11-03 2019-11-27 Sentinext Therapeutics Sdn Bhd Vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
JP5918870B2 (ja) 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
JP2015526062A (ja) 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
BR112015021880A2 (pt) 2013-03-13 2017-09-26 Novartis Ag rearranjo de vírus influenza b
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
AU2014276418A1 (en) 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
WO2015179979A1 (en) * 2014-05-28 2015-12-03 National Health Research Institutes Viral particles as immunogens against enterovirus infection and production thereof
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
KR102576962B1 (ko) 2015-07-07 2023-09-11 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
US20230000971A1 (en) 2019-11-18 2023-01-05 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (el) * 1974-01-14 1977-07-15 Sandoz Ag
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (ja) 1991-09-25 2000-11-13 松下電工株式会社 多重伝送システムの割込処理方法
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JP4610735B2 (ja) * 1998-06-01 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ワクチン抗原およびアジュバントの粘膜送達のためのヒアルロン酸ポリマーの使用
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
BRPI0010612B8 (pt) * 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2383105C (en) 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
AU3241501A (en) 1999-12-08 2001-06-18 Crucell Holland B.V. Method of administering adenovirus
CA2401117C (en) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
JP2004520144A (ja) 2001-04-27 2004-07-08 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム 新規ワクチン
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
WO2004056979A2 (en) 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
NZ543467A (en) * 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
MX342639B (es) 2003-05-28 2016-10-07 Wisconsin Alumni Res Found Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
RS51665B (en) * 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2525518T3 (es) * 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual

Also Published As

Publication number Publication date
US10655108B2 (en) 2020-05-19
DK1951296T4 (da) 2014-09-01
EA014062B1 (ru) 2010-08-30
AU2006310171A1 (en) 2007-05-10
AU2006310171B2 (en) 2011-02-17
ATE494906T1 (de) 2011-01-15
CN104474543A (zh) 2015-04-01
EP1951296A2 (en) 2008-08-06
JP5602366B2 (ja) 2014-10-08
EP2301572B1 (en) 2014-09-10
PL2301572T3 (pl) 2015-02-27
EP1951296B2 (en) 2014-07-23
JP2009513694A (ja) 2009-04-02
ES2359214T3 (es) 2011-05-19
WO2007052163A3 (en) 2007-09-07
CN101365480B (zh) 2014-11-05
BRPI0618094A2 (pt) 2011-08-16
JP7049761B2 (ja) 2022-04-07
EP2842572A1 (en) 2015-03-04
JP2020023557A (ja) 2020-02-13
SI1951296T2 (sl) 2014-09-30
JP2014198726A (ja) 2014-10-23
DK1951296T3 (da) 2011-03-28
HK1207828A1 (en) 2016-02-12
JP2011256209A (ja) 2011-12-22
PL1951296T5 (pl) 2015-06-30
EP2301572A1 (en) 2011-03-30
HK1129837A1 (en) 2009-12-11
SI1951296T1 (sl) 2011-04-29
US11466257B2 (en) 2022-10-11
DE602006019629D1 (de) 2011-02-24
EA200801221A1 (ru) 2008-10-30
PL1951296T3 (pl) 2011-09-30
CN101365480A (zh) 2009-02-11
ES2525518T3 (es) 2014-12-26
NZ567817A (en) 2012-01-12
AU2011201968B2 (en) 2014-08-28
AU2011201968A1 (en) 2011-05-19
JP6639077B2 (ja) 2020-02-05
US20200377864A1 (en) 2020-12-03
EP1951296B1 (en) 2011-01-12
PT2301572E (pt) 2014-12-22
JP2016185988A (ja) 2016-10-27
CA2627971A1 (en) 2007-05-10
KR20080081254A (ko) 2008-09-09
US20090304729A1 (en) 2009-12-10
ES2359214T5 (es) 2014-10-08
WO2007052163A2 (en) 2007-05-10
BRPI0618094A8 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
CY1120911T1 (el) Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1121159T1 (el) Μη-ενσωματουμενοι λεντiϊικοι φορεις
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CY1120136T1 (el) Μεθοδος για την αυξηση της ανοσοδραστικοτητας
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
DE602004025996D1 (de) Immortalisierte Entezelllinien zur Viruserzeugung
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
WO2010019262A3 (en) Polyvalent vaccine
MX2009006469A (es) Metodo de duplicacion del virus de la influenza en cultivo.
EA201001045A1 (ru) Модифицированный вирус гриппа
UA108902C2 (uk) Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
EA201291179A1 (ru) Органические пероксидные соединения для инактивации микроорганизмов
WO2012040266A3 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines